Development and internal validation of a risk prediction model for ipsilateral upper-limb lymphedema following breast cancer surgery - Report - MDSpire
Advertisement
Development and internal validation of a risk prediction model for ipsilateral upper-limb lymphedema following breast cancer surgery
Clinical Report: Predictive Model for Upper-Limb Lymphedema After Breast Cancer Surgery
Overview
This study developed and validated a predictive nomogram for breast cancer-related lymphedema (BCRL) using four key clinical variables. The model demonstrated excellent discriminative ability and may assist in identifying high-risk patients for early intervention.
Background
Breast cancer-related lymphedema (BCRL) significantly impacts the quality of life of survivors, leading to physical and psychosocial complications. Accurate prediction of BCRL is crucial for early preventive measures and improving postoperative outcomes. This study addresses the need for a clinically practical tool to stratify risk in breast cancer patients.
Data Highlights
Variable
Association with BCRL
Breast-conserving surgery
Lower risk
Pectoral nodes dissection
Higher risk
Higher N stage
Higher risk
Greater number of harvested lymph nodes
Higher risk
Key Findings
The nomogram included surgery type, pectoral nodes dissection, number of harvested lymph nodes, and N stage as predictors.
The model achieved an apparent AUC of 0.964 and a bootstrap optimism-corrected AUC of 0.954.
Calibration analysis indicated a calibration-in-the-large of 0.000, suggesting good model fit.
The apparent Brier score was 0.0469, indicating strong predictive accuracy.
Decision curve analysis showed favorable net benefit compared to treat-all and treat-none strategies.
Clinical Implications
The developed nomogram can serve as a supportive tool for clinicians to identify patients at higher risk for BCRL, allowing for targeted surveillance and preventive strategies. However, it should not replace clinical judgment and requires external validation before widespread implementation.
Conclusion
The predictive nomogram for BCRL demonstrates strong discrimination and potential clinical utility, highlighting the importance of early identification and intervention in at-risk breast cancer patients.
The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
